感染疾病物市場規模、佔有率和成長分析：按類型、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

2024 年全球抗感染藥物市場價值為 1354.3 億美元，預計到 2033 年將從 2025 年的 1376.1 億美元成長至 1563.7 億美元，在預測期（2026-2033 年）內複合年成長率為 1.61%。

全球感染疾病物市場的主要驅動力是感染疾病的不斷增加，這反過來又推動了抗生素、抗病毒藥物、抗真菌藥物和抗寄生蟲藥物的持續創新。該市場涵蓋處方藥、非處方藥和生物製藥，旨在預防和治療感染疾病，而日益嚴重的抗菌素抗藥性則顯著推高了市場需求。從廣譜抗生素轉向標靶治療（例如小分子化合物和單株抗體）凸顯了治療方法的演變。此外，療效不足的傳統藥物導致更高的發病率、更長的住院時間和飆升的醫療成本，促使人們投資新的療法和快速診斷工具。監管獎勵和官民合作關係對於將迫切需求轉化為商業機會、擴大新興市場的可及性以及透過綜合診斷和合理用藥措施支持永續成長至關重要。

全球感染疾病物市場的促進因素

日益嚴峻的抗生素抗藥性挑戰促使新型和改良型抗感染藥物的研發蓬勃發展。這一日益嚴重的問題促使許多公司和研究機構將重點放在創新的預防和治療策略上。競爭激烈的醫療保健產業推動了藥物發現、臨床開發和產品線拓展的投資機會。此外，這也為旨在加速產品週期和市場准入的夥伴關係和授權協議鋪平了道路。這種對創新的日益重視有望催生出多種新的治療方案，從而刺激各經濟領域的商業活動。

全球抗感染藥物市場的限制因素

影響全球感染疾病物市場的關鍵限制因素之一是新藥研發所需的巨額資金，此外還包括臨床試驗和法規核准的相關成本。這種沉重的財務負擔導致許多公司對進入感染疾病物領域猶豫不決。此外，漫長的藥物研發週期和市場前景的不確定性也使得這些投資越來越難以證明其合理性。因此，從開發平臺最終上市的新藥數量正在減少，導致在研項目數量下降，並促使企業集中資源，專注於更精簡的產品組合。

全球感染疾病物市場趨勢

全球感染疾病物市場正日益受到精準醫療的影響，精準醫療的特徵是分子譜分析和病原體特異性生物標記的發現。這種轉變使得抗感染疾病治療方法能夠根據個別患者的具體情況進行客製化，並加速了窄頻譜產品和宿主標靶治療方法的研發。製藥公司正在利用伴隨診斷和個人化臨床試驗設計等臨床創新，根據特定病原體的特徵來客製化抗感染疾病療法。這一趨勢正在促進診斷試劑製造商、生物技術公司和醫療服務提供者之間的合作，加速標靶治療策略的推廣應用，並旨在改善感染疾病控制的臨床療效。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球感染疾病物市場規模：按類型分類

• 抗菌劑
• 抗病毒藥物
• 抗真菌劑
• 其他

全球感染疾病物市場規模：依給藥途徑分類

• 口服
• 腸外
• 外用
• 其他

全球感染疾病物市場規模：依最終用戶分類

• 醫院
• 居家照護環境
• 診所
• 其他

全球感染疾病物市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer
• Gilead Sciences
• GlaxoSmithKline
• Merck & Co
• Johnson & Johnson
• Novartis
• Roche Holding
• Sanofi
• AstraZeneca
• Bayer
• AbbVie
• Bristol-Myers Squibb
• Eli Lilly and Company
• Takeda Pharmaceutical
• Abbott Laboratories
• Astellas Pharma
• Sun Pharmaceutical Industries
• Cipla
• Dr. Reddy's Laboratories
• Lupin

結論與建議

Global Anti-Infective Agents Market size was valued at USD 135.43 Billion in 2024 and is poised to grow from USD 137.61 Billion in 2025 to USD 156.37 Billion by 2033, growing at a CAGR of 1.61% during the forecast period (2026-2033).

The global anti-infective agents market is primarily driven by the increasing prevalence of infectious diseases, prompting continuous innovation in antibiotics, antivirals, antifungals, and antiparasitics. This market encompasses prescription medications, over-the-counter products, and biologics aimed at preventing and treating infections, with rising antimicrobial resistance contributing significantly to demand. The shift from broad-spectrum antibiotics to targeted therapies such as small molecules and monoclonal antibodies highlights the evolution in treatment approaches. Furthermore, ineffective legacy drugs lead to increased morbidity, extended hospital stays, and higher healthcare costs, spurring investment in novel therapeutics and rapid diagnostic tools. Regulatory incentives and public-private partnerships are vital in transforming urgent needs into opportunities, expanding access in emerging markets, and supporting sustainable growth through integrated diagnostics and stewardship initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti-Infective Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti-Infective Agents Market Segments Analysis

Global anti-infective agents market is segmented by type, route of administration, end-user and region. Based on type, the market is segmented into antibacterial agents, antiviral agents, antifungal agents and others. Based on route of administration, the market is segmented into oral, parenteral, topical and others. Based on end-user, the market is segmented into hospitals, homecare settings, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti-Infective Agents Market

The growing challenge of antimicrobial resistance is driving a surge in the development of new and enhanced anti-infective agents. This escalating issue has prompted numerous companies and research institutions to focus on innovative prevention and treatment strategies. The competitive healthcare landscape fosters investment opportunities in discovery, clinical development, and pipeline expansion. Moreover, it paves the way for collaborative partnerships and licensing agreements aimed at accelerating product cycles and market entry. This heightened emphasis on innovation is set to yield a variety of new therapeutic options, thereby stimulating commercial activity across diverse sectors of the economy.

Restraints in the Global Anti-Infective Agents Market

One significant constraint impacting the Global Anti-Infective Agents market is the substantial financial investment required for the research and development of new drugs, coupled with the costs associated with conducting clinical trials and obtaining regulatory approvals. This financial burden deters many companies from entering the anti-infective sector. Furthermore, the lengthy process of drug development and the inherent uncertainties regarding market success create an environment where justifying such investments becomes increasingly challenging. As a result, fewer new drugs are emerging from the development pipeline, leading to a decline in the number of active projects and prompting companies to consolidate their resources to focus on a more limited range of offerings.

Market Trends of the Global Anti-Infective Agents Market

The Global Anti-Infective Agents market is increasingly influenced by the integration of precision therapy, characterized by the emergence of molecular profiling and pathogen-specific biomarker discovery. This shift enables the customization of anti-infective treatment regimens tailored to individual patient profiles, fostering the development of narrow-spectrum products and host-targeted therapies. Pharmaceutical companies are leveraging clinical innovations such as companion diagnostics and tailored trial designs, aligning anti-infective therapy with specific pathogen attributes. This trend is fostering collaborative efforts among diagnostics, biotechnology firms, and healthcare providers, aimed at accelerating the adoption of targeted therapeutic strategies and enhancing clinical outcomes in the management of infectious diseases.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Anti-infective Agents Market Size by Type & CAGR (2026-2033)

• Market Overview
• Antibacterial Agents
• Antiviral Agents
• Antifungal Agents
• Others

Global Anti-infective Agents Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Topical
• Others

Global Anti-infective Agents Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare Settings
• Clinics
• Others

Global Anti-infective Agents Market Size & CAGR (2026-2033)

• North America (Type, Route of Administration, End-User)
  • US
  • Canada
• Europe (Type, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Route of Administration, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations